Heron Therapeutics appoints Thomas Cusack to board under Rubric Capital agreement

HERON THERAPEUTICS, INC. /DE/

Thomas Cusack appointed to Heron's board effective Oct 27, 2025; term expires at 2026 annual meeting.
Cusack was Managing Director at Starboard Value LP (approx. $9B AUM) from 2011-2025.
Appointment made pursuant to Cooperation Agreement with Rubric Capital Management LP dated Aug 8, 2025.
Cusack will serve on the Nominating and Corporate Governance Committee.
Director compensation follows standard non-employee director program described in April 2025 proxy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.